Alendronic acid

Generic Name: Alendronic acid

Brand Names: Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₃NO_₇P_₂

CAS Number: 66376-36-1

Unique Ingredient Identifier: X1J18R4W8P

Background: Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.

Indication: Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.

Associated Conditions: Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget’s Disease

Associated Therapies: -

Clinical Trials

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

Phase 3

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: Alendronate

First Posted Date: 2012-08-06

Last Posted Date: 2020-12-11

Lead Sponsor: Radius Health, Inc.

Target Recruit Count: 1139

Registration Number: NCT01657162

Stem Cell Recruitment in Osteoporosis Therapy

Not Applicable

Terminated

Conditions: Low Bone Density

Interventions: Dietary Supplement: calcium and vitamin D
Drug: Teriparatide
Drug: Alendronate

First Posted Date: 2012-08-03

Last Posted Date: 2020-08-21

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 55

Registration Number: NCT01656629

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

Phase 3

Completed

Conditions: Postmenopausal Women With Osteoporosis

Interventions: Biological: Romosozumab
Drug: Alendronate
Drug: Placebo to Romosozumab
Drug: Placebo to Alendronate

First Posted Date: 2012-06-29

Last Posted Date: 2022-11-08

Lead Sponsor: Amgen

Target Recruit Count: 4093

Registration Number: NCT01631214

Locations: 🇬🇧
Research Site, Warwick, United Kingdom

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

Phase 3

Withdrawn

Conditions: Osteoporosis
Postmenopausal Osteoporosis

Interventions: Drug: Odanacatib
Drug: Alendronate
Dietary Supplement: Cholecalciferol (Vitamin D3)
Other: Placebo (odanacatib)
Dietary Supplement: Calcium carbonate
Other: Placebo (alendronate)

First Posted Date: 2012-03-13

Last Posted Date: 2015-08-27

Lead Sponsor: Merck Sharp & Dohme LLC

Registration Number: NCT01552122

Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy

Phase 3

Terminated

Conditions: Osteoporosis

Interventions: Drug: Placebo
Drug: Alendronate

First Posted Date: 2012-01-19

Last Posted Date: 2019-02-12

Lead Sponsor: Evangelisches Krankenhaus Lutherhaus gGmbH

Target Recruit Count: 436

Registration Number: NCT01512446

Locations: 🇩🇪
Department of Internal Medicine III, Alfried Krupp Krankenhaus Essen Steele, Essen, Germany

Testosterone and Alendronate in Hypogonadal Men

Phase 2

Terminated

Conditions: Hypogonadism
Osteopenia
Osteoporosis

Interventions: Drug: Testosterone
Drug: Alendronate
Drug: Placebo Alendronate
Drug: Placebo Testosterone

First Posted Date: 2011-10-27

Last Posted Date: 2023-10-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 44

Registration Number: NCT01460654

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Pilot Study of Fosamax in Spinal Cord Injury

Not Applicable

Terminated

Conditions: Spinal Cord Injury
Osteoporosis

Interventions: Drug: Fosamax
Drug: Placebo

First Posted Date: 2010-05-27

Last Posted Date: 2016-01-29

Lead Sponsor: University of Rochester

Target Recruit Count: 1

Registration Number: NCT01131884

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
University of Rochester Physical Medicine and Rehabilitation, Rochester, New York, United States

A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: ibandronate [Bonviva/Boniva]
Drug: alendronate

First Posted Date: 2010-05-21

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 6054

Registration Number: NCT01128257

Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS)

Completed

Conditions: Ankylosing Spondylitis
Osteoporosis

Interventions: Drug: alendronate

First Posted Date: 2010-04-16

Last Posted Date: 2016-08-09

Lead Sponsor: Göteborg University

Target Recruit Count: 16

Registration Number: NCT01104987

Locations: 🇸🇪
Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden

Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)

Completed

Conditions: Adenocarcinoma
Esophageal Cancer
Squamous Cell Carcinoma

Interventions: Drug: Alendronate
Drug: Etidronate
Drug: Ibandronate
Drug: Risedronate
Drug: Raloxifene

First Posted Date: 2010-03-01

Last Posted Date: 2022-02-03

Lead Sponsor: Organon and Co

Target Recruit Count: 684815

Registration Number: NCT01077817

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy